Edward Cha

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Immune Response in Stat2 Knockout Mice

Christopher Y. Park, Suzanne Li, Edward Cha et al. · Immunity · 2000 · 403 citations · Full text

Inflammation, Autoimmune Disease, Immune Cell Development +7

Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Edward Cha, Mark Klinger, Yafei Hou et al. · Science Translational Medicine · 2014 · 376 citations · Full text

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto et al. · Journal for ImmunoTherapy of Cancer · 2020 · 260 citations · Full text

New Agents, Immunology, Immunoediting +17

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Ryan J. Sullivan, Omid Hamid, René González et al. · Nature Medicine · 2019 · 233 citations

Medicine, Melanoma, Braf-mutated Melanoma Patients +4